Product Details
Product Name:
SU4312 |
CAS No.:
5812-07-7 |
Purity:
97.79% |
Supply Ability:
10g |
Release date:
2025/07/20 |
Product Introduction
Bioactivity
Name | SU4312 |
Description | SU-4312, also known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). SU4312 (SU 4312) unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Solubility Information | DMSO : 55 mg/mL (208.08 mM), Sonication is recommended.
|
Keywords | VEGFR | Vascular endothelial growth factor receptor | SU-4312 | SU4312 | Platelet-derived growth factor receptor | PDGFR | NSC-86429 | NSC86429 | Inhibitor | inhibit |
Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Taxifolin | Sorafenib | Regorafenib | Sanguinarine chloride | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:874374-25-1
$58.00 / 1mg
-
CAS:90828-16-3
$80.00 / 1mg
-
CAS:66648-50-8
$78.00 / 50mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |